|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human virus. The HA tag is derived from the HA-molecule corresponding to amino acids 98-106 has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA tag, which does not appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
The actual HA tag is as follows: 5' TAC CCA TAC GAT GTT CCA GAT TAC GCT 3' or 5' TAT CCA TAT GAT GTT CCA GAT TAT GCT 3' The amino acid sequence is: YPYDVPDYA.
|Mouse SFTPD ORF mammalian expression plasmid, C-GFPSpark tag||MG50205-ACG|
|Mouse SFTPD ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50205-ACR|
|Mouse SFTPD ORF mammalian expression plasmid, C-Flag tag||MG50205-CF|
|Mouse SFTPD ORF mammalian expression plasmid, C-His tag||MG50205-CH|
|Mouse SFTPD ORF mammalian expression plasmid, C-Myc tag||MG50205-CM|
|Mouse SFTPD ORF mammalian expression plasmid, C-HA tag||MG50205-CY|
|Mouse SFTPD Gene cDNA clone plasmid||MG50205-M|
|Mouse SFTPD ORF mammalian expression plasmid, N-Flag tag||MG50205-NF|
|Mouse SFTPD ORF mammalian expression plasmid, N-His tag||MG50205-NH|
|Mouse SFTPD ORF mammalian expression plasmid, N-Myc tag||MG50205-NM|
|Mouse SFTPD ORF mammalian expression plasmid, N-HA tag||MG50205-NY|
|Mouse SFTPD natural ORF mammalian expression plasmid||MG50205-UT|
|Learn more about expression Vectors|
Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.